Maria Papaleontiou1, Deborah A Levine2, David Reyes-Gastelum1, Sarah T Hawley3, Mousumi Banerjee4, Megan R Haymart1. 1. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. 2. Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. 3. Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. 4. School of Public Health, Department of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA.
Abstract
CONTEXT: Stroke is a leading cause of death and disability and there is a need to identify modifiable risk factors. OBJECTIVE: We aimed to determine the relationship between thyroid hormone treatment intensity and incidence of atrial fibrillation and stroke. METHODS: We conducted a retrospective cohort study using data from the Veterans Health Administration between 2004 and 2017, with a median follow-up of 59 months. The study population comprised 733 208 thyroid hormone users aged ≥18 years with at least 2 thyroid stimulating hormone (TSH) measurements between thyroid hormone initiation and incident event (atrial fibrillation or stroke) or study conclusion (406 030 thyroid hormone users with at least 2 free thyroxine [T4] measurements). RESULTS: Overall, 71 333/643 687 (11.08%) participants developed incident atrial fibrillation and 41 931/663 809 (6.32%) stroke. In multivariable analyses controlling for pertinent factors such as age, sex, and prior history of atrial fibrillation, higher incidence of stroke was associated with low TSH or high free T4 levels (ie, exogenous hyperthyroidism; eg, TSH <0.1 mIU/L; OR 1.33; 95% CI, 1.24-1.43; free T4>1.9 ng/dL, OR 1.17, 95% CI 1.06-1.30) and high TSH or low free T4 levels (ie, exogenous hypothyroidism; eg, TSH >5.5 mIU/L; OR 1.29; 95% CI, 1.26-1.33; free T4 <0.7 ng/dL; OR 1.29; 95% CI, 1.22-1.35) compared with euthyroidism (TSH >0.5-5.5 mIU/L and free T4 0.7-1.9 ng/dL). Risk of developing atrial fibrillation and stroke was cumulative over time for both patients with exogenous hyperthyroidism and hypothyroidism. CONCLUSION: Both exogenous hyper- and hypothyroidism were associated with increased risk of stroke, highlighting the importance of patient medication safety.
CONTEXT: Stroke is a leading cause of death and disability and there is a need to identify modifiable risk factors. OBJECTIVE: We aimed to determine the relationship between thyroid hormone treatment intensity and incidence of atrial fibrillation and stroke. METHODS: We conducted a retrospective cohort study using data from the Veterans Health Administration between 2004 and 2017, with a median follow-up of 59 months. The study population comprised 733 208 thyroid hormone users aged ≥18 years with at least 2 thyroid stimulating hormone (TSH) measurements between thyroid hormone initiation and incident event (atrial fibrillation or stroke) or study conclusion (406 030 thyroid hormone users with at least 2 free thyroxine [T4] measurements). RESULTS: Overall, 71 333/643 687 (11.08%) participants developed incident atrial fibrillation and 41 931/663 809 (6.32%) stroke. In multivariable analyses controlling for pertinent factors such as age, sex, and prior history of atrial fibrillation, higher incidence of stroke was associated with low TSH or high free T4 levels (ie, exogenous hyperthyroidism; eg, TSH <0.1 mIU/L; OR 1.33; 95% CI, 1.24-1.43; free T4>1.9 ng/dL, OR 1.17, 95% CI 1.06-1.30) and high TSH or low free T4 levels (ie, exogenous hypothyroidism; eg, TSH >5.5 mIU/L; OR 1.29; 95% CI, 1.26-1.33; free T4 <0.7 ng/dL; OR 1.29; 95% CI, 1.22-1.35) compared with euthyroidism (TSH >0.5-5.5 mIU/L and free T4 0.7-1.9 ng/dL). Risk of developing atrial fibrillation and stroke was cumulative over time for both patients with exogenous hyperthyroidism and hypothyroidism. CONCLUSION: Both exogenous hyper- and hypothyroidism were associated with increased risk of stroke, highlighting the importance of patient medication safety.
Authors: Annabelle Santos Volgman; C Noel Bairey Merz; Emelia J Benjamin; Anne B Curtis; Margaret C Fang; Kathryn J Lindley; Carl J Pepine; Marmar Vaseghi; Albert L Waldo; Nanette K Wenger; Andrea M Russo Journal: J Am Coll Cardiol Date: 2019-12-03 Impact factor: 24.094
Authors: Anne R Cappola; Linda P Fried; Alice M Arnold; Mark D Danese; Lewis H Kuller; Gregory L Burke; Russell P Tracy; Paul W Ladenson Journal: JAMA Date: 2006-03-01 Impact factor: 56.272
Authors: Seth S Martin; Natalie Daya; Pamela L Lutsey; Kunihiro Matsushita; Anna Fretz; John W McEvoy; Roger S Blumenthal; Josef Coresh; Philip Greenland; Anna Kottgen; Elizabeth Selvin Journal: J Clin Endocrinol Metab Date: 2017-09-01 Impact factor: 5.958
Authors: Robert W Flynn; Sandra R Bonellie; Roland T Jung; Thomas M MacDonald; Andrew D Morris; Graham P Leese Journal: J Clin Endocrinol Metab Date: 2009-11-11 Impact factor: 5.958
Authors: Stephan D Fihn; Joseph Francis; Carolyn Clancy; Christopher Nielson; Karin Nelson; John Rumsfeld; Theresa Cullen; Jack Bates; Gail L Graham Journal: Health Aff (Millwood) Date: 2014-07 Impact factor: 6.301
Authors: Lily L Somwaru; Alice M Arnold; Neha Joshi; Linda P Fried; Anne R Cappola Journal: J Clin Endocrinol Metab Date: 2009-01-06 Impact factor: 5.958
Authors: Susan R Heckbert; Thomas R Austin; Paul N Jensen; Lin Y Chen; Wendy S Post; James S Floyd; Elsayed Z Soliman; Richard A Kronmal; Bruce M Psaty Journal: Circ Arrhythm Electrophysiol Date: 2020-01-14
Authors: Josh M Evron; Scott L Hummel; David Reyes-Gastelum; Megan R Haymart; Mousumi Banerjee; Maria Papaleontiou Journal: JAMA Netw Open Date: 2022-05-02